The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI versus pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Committee recommended the unblinding of the study. "The CARTITUDE-4 study represents the first Phase 3 program in our comprehensive clinical development strategy for CARVYKTI, and further demonstrates our commitment to advance the treatment of patients with relapsed/refractory multiple myeloma," said Jordan Schecter, M.D., Vice President, Clinical Development Cellular Therapy Program, Janssen Research & Development, LLC. "We look forward to the presentation of the data from the CARTITUDE-4 study at a future medical meeting."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on JNJ:
- J&J conference call comments ‘a good sign’ for Protagonist, says JMP Securities
- Johnson & Johnson Reports Earnings: Did it Beat Estimate Forecasts?
- Johnson & Johnson says assuming a lot of inflationary carryover in 2023
- Johnson & Johnson sees ‘above market growth’ in Pharmaceutical segment in FY23
- Johnson & Johnson expects FY23 OPEX leverage offset by inflationary pressures